Honoured to receive support from #diabetestutkimus, #diabetefi for our ongoing #diabetesresearch @HelsinkiUniMed
Job alert...join us
jobs.helsinki.fi/job-invite/…
#T1D #diabetesResearch #postdoc #postdocposition @HelsinkiUniMed
I am grateful to @novonordiskfond for funding a project grant to understand the mechanism for differential vulnerability of alpha and beta cells in #T1D through stem cells islets; looking for a motivated #postdoc ! @HelsinkiUniMed @helsinkiuni #Type1diabetes
Vikash Chandra retweeted
🧬 Exciting new episode alert! 🧬
Join us as Vikash Chandra discusses potential candidate genes for drug targeting in #Type1Diabetes. Dive into groundbreaking insights and innovative research.
Watch now: youtu.be/GGUGd3QFODs
#DiabetesResearch #DrugDiscovery #TSS
25%Yes, I have watched it!
75%I will go watch it now!
4 votes • Final results Vikash Chandra retweeted
Thursday! - 9 AM PT//12 PM ET
📢: tinyurl.com/3uhxm7mx
@DiabetesnPOD @ULBCDiabRes @AMP_CMDKP
@ufdiabete @IUSweetTweets @T1D_researchers
@helmholtz_diabc @PennIDOM
@DiabResearch @Diabetes_DRI @StanfordDRC
@BCDiabResNet @JoslinDiabetes @Bruskolab
@helsinkiuni @Dr_V_Chandra
Vikash Chandra retweeted
Very happy to see our long-term project on the functional characterization of an RFX6 mutation enriched in Finns published in @DiabetologiaJnl. Superb work by @Hazemibrahimi. Read here: rdcu.be/dHX38
Vikash Chandra retweeted
We're thrilled to announce that #EISG24_Helsinki 🇫🇮 is now SOLD OUT! 📷 Get ready for an exciting week of islet biology! We apologize to those who missed out, please register to the waiting list. We will consider the possibility of virtual attendance: elomake.helsinki.fi/lomakkee…
Vikash Chandra retweeted
Register now to the European Islet Study Group meeting in Helsinki, Finland, 18-20 June 2024 🚨Early-bird registration and abstract deadline is approaching, do not miss your chance, limited seats availablea and they are quickly filling up! helsinki.fi/en/conferences/e……Please RT ;)
Vikash Chandra retweeted
Thrilled to announce that registration and abstract submission for European Islet Study Group meeting in Helsinki, Finland, 18-20 June 2024 is NOW OPEN! helsinki.fi/en/conferences/e…
🚨Early-bird registration is March 15th, limited seats available🚨
Please RT ;)
Vikash Chandra retweeted
LVM3 M4/Chandrayaan-3 Mission:
LVM3 M4 vehicle🚀 successfully launched Chandrayaan-3🛰️ into orbit.
Vikash Chandra retweeted
I love a muscle image, but this Drosophila one is top of the class! Beautiful
Fly muscles m.cmpgn.page/xm2FMK?sre=RvJw… @andor
Great to present our latest research by Sophia at 19th Immunology of Diabetes Society #IDS #Paris 23 conference #T1d #Diabetes #Immunology @OtonkoskiL @Innodiagroup @HelsinkiUniMed @OtonkoskiT
Our research topic "Revisiting cellular metabolism and Type1 diabetes" is now online in @FrontEndocrinol frontiersin.org/research-top…
with @SwethaGopalakr2 and Latif Rachdi
Vikash Chandra retweeted
According to a study @helsinkiuni, type 1 diabetes could be prevented by inhibiting a gene associated with the onset of the disease. @OtonkoskiL @OtonkoskiT @Dr_V_Chandra #WorldDiabetesDay helsinki.fi/en/news/public-h…
Vikash Chandra retweeted
A promising drug candidate discovered for the prevention of type 1 #diabetes @helsinkiuni @NatureComms doi.org/gq5pxb medicalxpress.com/news/2022-…
Vikash Chandra retweeted
Our article is featured in the top 50 of the stem cells category @NatureComms
nature.com/collections/pkgzt…
Vikash Chandra retweeted
Helsinkiläistutkijoilta hyviä uutisia tyypin 1 diabetesta sairastaville – lääke ehkä löydetty yle.fi/uutiset/74-20003092?u…
Vikash Chandra retweeted
Kantasolututkimus paljastaa uuden palan diabeteksen mysteeripalapelistä! Voisiko TYK2 inhibiittori olla tyyppi 1 diabeteksen tulevaisuuden hoito?! Congrats Otonkoski-group! New avenues to treat type 1 diabetes! @HUS_fi @HelsinkiUniMed @Laakarilehti @DuodecimFi
Checkout our new paper deciphering the role of the T1D gene TYK2 on beta-cell development and interferon responses.
Thankful for the great collaborative effort!
@Dr_V_Chandra @OtonkoskiT @MetaStem_Center @helsinkiuni @STEMMProgram @Innodiagroup
⬇️
nature.com/articles/s41467-0…
Glad to present our work TYK2 inhibition as a potential therapeutic target to halt #T1D progression. @OtonkoskiT @Hazemibrahimi @STEMMProgram @MetaStem_Center @helsinkiunimed @Innodiagroup @OtonkoskiL @NatureComms nature.com/articles/s41467-0…
Also on a brief note, feeling extremely honoured to be awarded docentship in experimental endocrinology from @HelsinkiUniMed Thanks to my mentor @OtonkoskiT and @OtonkoskiL for all the support 🙏

















